13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
41 檔
29.8%
During the Q1 2026 filing period, Catalio Capital Management, LP (CIK: 0001958125) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $532.1M across 41 reported positions.
Catalio Capital Management, LP executed strategic sector rebalancing during Q1 2026, establishing 10 new positions while fully exiting 14 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 9.82% | -9.22% | -14.27% | |
| 2 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.70% | -0.33% | — | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 6.17% | -6.17% | EXIT | |
| 4 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 5.33% | -0.86% | -35.06% | |
| 5 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.09% | -0.10% | -12.80% | |
| 6 | GILD | Gilead Sciences Inc | Stock-Healthcare | 4.77% | +1.62% | -43.35% | |
| 7 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.50% | -4.50% | EXIT | |
| 8 | DFTX | Definium Therapeutics Inc | Stock-Other | 4.10% | +0.87% | — | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 4.04% | -4.04% | EXIT | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.92% | -3.92% | EXIT | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.72% | -1.74% | +423.41% | |
| 12 | INCY | Incyte CORP | Stock-Healthcare | 3.58% | +0.50% | — | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.97% | -2.97% | EXIT | |
| 14 | NTRA | Natera Inc | Stock-Healthcare | 2.96% | +1.23% | +13.86% | |
| 15 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 2.73% | +0.30% | — | |
| 16 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.57% | +0.22% | +0.98% | |
| 17 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.48% | +0.81% | +32.30% | |
| 18 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.42% | -0.30% | -22.69% | |
| 19 | MANE | Veradermics Inc | Stock-Other | 2.29% | -1.23% | — | |
| 20 | ADPT | Adaptive Biotechnologies | Stock-Other | 2.10% | -2.10% | EXIT | |
| 21 | HTFL | Heartflow Inc | Stock-Other | 2.05% | +1.17% | +254.47% | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.79% | -1.79% | EXIT | |
| 23 | QURE | uniQure N.V. | Stock-Other | 1.68% | -1.68% | EXIT | |
| 24 | IRON | Disc Medicine Inc | Stock-Other | 1.64% | +0.55% | +11.37% | |
| 25 | SEPN | Septerna Inc | Stock-Other | 1.48% | +1.89% | — | |
| 26 | ABVX | Abivax Sa-adr | Stock-Other | 1.10% | -1.10% | EXIT | |
| 27 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.07% | -0.05% | -45.56% | |
| 28 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.06% | +0.20% | +30.16% | |
| 29 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 1.04% | +0.69% | +527.84% | |
| 30 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 0.67% | -0.67% | EXIT | |
| 31 | TARA | Protara Therapeutic Inc | Stock-Other | 0.63% | -0.26% | -59.89% | |
| 32 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.58% | -0.57% | EXIT | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.56% | -0.56% | EXIT | |
| 34 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.54% | -0.54% | EXIT | |
| 35 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.53% | +0.35% | — | |
| 36 | GUTS | Fractyl Health Inc | Stock-Other | 0.53% | +0.39% | — | |
| 37 | HYPR | Hyperfine Inc | Stock-Other | 0.30% | +0.03% | — | |
| 38 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.15% | -0.03% | — | |
| 39 | ATAI | Ataibeckley Inc | Stock-Other | 0.15% | +0.05% | — | |
| 40 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.10% | -0.03% | — | |
| 41 | OM | Outset Medical Inc | Stock-Other | 0.09% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | +5.1% | -14.27% | Trim |
| 2 | 430 | Terns Pharmaceuticals Inc | +3.5% | +198.65% | Add |
| 3 | RARE | Ultragenyx Pharmaceutical In | +3.1% | +423.41% | Add |
| 4 | ASND | Ascendis Pharma A/S | +1.7% | +8.26% | Add |
| 5 | HTFL | Heartflow Inc | +1.5% | +254.47% | Add |
| 6 | SLNOEUR | Soleno Therapeutics Inc | +1.1% | +60.35% | Add |
| 7 | KPTI | Karyopharm Therapeutics Inc | +0.9% | +527.84% | Add |
| 8 | ELDN | Eledon Pharmaceuticals Inc | +0.7% | +30.16% | Add |
| 9 | SNDX | Syndax Pharmaceuticals Inc | +0.7% | -12.80% | Trim |
| 10 | QURE | uniQure N.V. | +0.5% | +70.32% | Add |
| 11 | NTRA | Natera Inc | +0.4% | +13.86% | Add |
| 12 | MLYS | Mineralys Therapeutics Inc | +0.4% | +32.30% | Add |
| 13 | IRON | Disc Medicine Inc | +0.1% | +11.37% | Add |
| 14 | CYTK | Cytokinetics Inc | +0.1% | -16.60% | Trim |
| 15 | FTH | Faeth Therapeutics Inc | +0.1% | — | Unchanged |
| 16 | HYPR | Hyperfine Inc | +0.1% | — | Unchanged |
| 17 | SEPN | Septerna Inc | 0% | — | Unchanged |
| 18 | OM | Outset Medical Inc | 0% | — | Unchanged |
| 19 | MGX | Metagenomi Therapeutics Inc | — | — | Unchanged |
| 20 | ADPT | Adaptive Biotechnologies | -0.3% | -11.98% | Trim |
| 21 | EW | Edwards Lifesciences CORP | -0.4% | -22.69% | Trim |
| 22 | GPCR | Structure Therapeutics Inc | -0.5% | +0.98% | Add |
| 23 | DYN | Dyne Therapeutics Inc | -0.7% | -45.56% | Trim |
| 24 | TARA | Protara Therapeutic Inc | -0.7% | -59.89% | Trim |
| 25 | BMY | Bristol-myers Squibb Co | -0.9% | -35.06% | Trim |
| 26 | ABVX | Abivax Sa-adr | -1.3% | -52.10% | Trim |
| 27 | PHAT | Phathom Pharmaceuticals Inc | -1.5% | -64.55% | Trim |
| 28 | GILD | Gilead Sciences Inc | -1.5% | -43.35% | Trim |
| 29 | SUPN | Supernus Pharmaceuticals Inc | -1.6% | -75.91% | Trim |
| 30 | GUTS | Fractyl Health Inc | -1.6% | — | Unchanged |
| 31 | BSX | Boston Scientific CORP | -2.2% | -16.95% | Trim |
| 32 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 33 | BBOT | Bridgebio Oncology Therapeut | — | EXIT | Sold out |
| 34 | LLY | Eli Lilly & Co | — | EXIT | Sold out |
| 35 | JNJ | Johnson & Johnson | — | EXIT | Sold out |
| 36 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 37 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 38 | INCY | Incyte CORP | — | NEW | New buy |
| 39 | ISRG | Intuitive Surgical Inc | — | EXIT | Sold out |
| 40 | CRVS | Corvus Pharmaceuticals Inc | — | NEW | New buy |
| 41 | MANE | Veradermics Inc | — | NEW | New buy |
| 42 | ADMA | Adma Biologics Inc | — | EXIT | Sold out |
| 43 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 44 | OCUL | Ocular Therapeutix Inc | — | EXIT | Sold out |
| 45 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 46 | OLMA | Olema Pharmaceuticals Inc | — | EXIT | Sold out |
| 47 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 48 | GRAL | Grail Inc | — | EXIT | Sold out |
| 49 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 50 | IMCR | Immunocore Holdings Plc-adr | — | NEW | New buy |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 41 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DNTH, BBIO, ASND) accounted for 29.8% of total reported equity market value during Q1 2026.
Top New Position Initiated
BBIO
市值: $32.1M
Top Position Liquidated / Trimmed
BBOT
前期市值: $31.4M
During Q1 2026, Catalio Capital Management, LP's top holdings by market value included DNTH (9.8%)、BBIO (6.7%)、ASND (6.2%). The largest single position, DNTH, represented 9.8% of total portfolio value.
In Q1 2026, Catalio Capital Management, LP made 49 total portfolio adjustments, initiating 10 new buys, adding to 12 positions, trimming 13 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.